WO2000026185A3 - Solution d'omeprazole et methode d'utilisation associee - Google Patents

Solution d'omeprazole et methode d'utilisation associee Download PDF

Info

Publication number
WO2000026185A3
WO2000026185A3 PCT/US1999/025592 US9925592W WO0026185A3 WO 2000026185 A3 WO2000026185 A3 WO 2000026185A3 US 9925592 W US9925592 W US 9925592W WO 0026185 A3 WO0026185 A3 WO 0026185A3
Authority
WO
WIPO (PCT)
Prior art keywords
metal
group
proton pump
pump inhibitor
bicarbonate salt
Prior art date
Application number
PCT/US1999/025592
Other languages
English (en)
Other versions
WO2000026185A9 (fr
WO2000026185A2 (fr
Inventor
Jeffrey O Phillips
Original Assignee
Univ Missouri
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Missouri filed Critical Univ Missouri
Priority to AU19071/00A priority Critical patent/AU1907100A/en
Publication of WO2000026185A2 publication Critical patent/WO2000026185A2/fr
Publication of WO2000026185A3 publication Critical patent/WO2000026185A3/fr
Publication of WO2000026185A9 publication Critical patent/WO2000026185A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une méthode de traitement d'acidité gastrique par administration, à un patient, d'une composition pharmaceutique contenant un inhibiteur de pompe à proton dans un support acceptable sur le plan pharmaceutique, comprenant un sel bicarbonaté d'un métal du groupe IA, qui consiste à administrer une forme à dosage unique qui ne nécessite aucune administration ultérieure de sel bicarbonaté de métal du groupe IA. Une composition pharmaceutique comprend une formulation sèche d'inhibiteur de pompe à proton dans un support acceptable sur le plan pharmaceutique, comprenant un sel bicarbonaté d'un métal du groupe IA. L'invention concerne aussi une composition pharmaceutique destinée à fabriquer une formulation sèche d'un inhibiteur de proton qui comprend un inhibiteur de pompe à proton et un sel bicarbonaté d'un métal du groupe IA sous une forme adaptée au stockage, la formulation sèche de la composition convenant à l'administration par voie entérale.
PCT/US1999/025592 1998-10-30 1999-10-29 Solution d'omeprazole et methode d'utilisation associee WO2000026185A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU19071/00A AU1907100A (en) 1998-10-30 1999-10-29 Omeprazole solution and method of using same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18342298A 1998-10-30 1998-10-30
US09/183,422 1998-10-30

Publications (3)

Publication Number Publication Date
WO2000026185A2 WO2000026185A2 (fr) 2000-05-11
WO2000026185A3 true WO2000026185A3 (fr) 2000-08-10
WO2000026185A9 WO2000026185A9 (fr) 2000-09-21

Family

ID=22672726

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/025592 WO2000026185A2 (fr) 1998-10-30 1999-10-29 Solution d'omeprazole et methode d'utilisation associee

Country Status (2)

Country Link
AU (1) AU1907100A (fr)
WO (1) WO2000026185A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6780882B2 (en) 1996-01-04 2004-08-24 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
USRE45198E1 (en) 1996-01-04 2014-10-14 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
MY137726A (en) 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
EP2596792A1 (fr) 2002-10-16 2013-05-29 Takeda Pharmaceutical Company Limited Préparations solides stables
TWI337877B (en) * 2003-07-18 2011-03-01 Santarus Inc Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853230A (en) * 1986-04-30 1989-08-01 Aktiebolaget Hassle Pharmaceutical formulations of acid labile substances for oral use
US5753265A (en) * 1994-07-08 1998-05-19 Astra Aktiebolag Multiple unit pharmaceutical preparation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853230A (en) * 1986-04-30 1989-08-01 Aktiebolaget Hassle Pharmaceutical formulations of acid labile substances for oral use
US5753265A (en) * 1994-07-08 1998-05-19 Astra Aktiebolag Multiple unit pharmaceutical preparation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NAKAGAWA ET AL.: "Phase I study of Lansoprazole (AG-1749), anticulcer agent", JOURNAL OF CLINICAL THERAPEUTICS & MEDICINES,, vol. 7, no. 1, January 1991 (1991-01-01), pages 33 - 50, XP002928123 *
PILBRANT ET AL.: "Development of an oral formulation of omeprazole", SCAND J. GASTROENTEROL.,, vol. 20, (SUPPL. 108), 1985, pages 113 - 120, XP002928124 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6780882B2 (en) 1996-01-04 2004-08-24 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
USRE45198E1 (en) 1996-01-04 2014-10-14 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them

Also Published As

Publication number Publication date
WO2000026185A9 (fr) 2000-09-21
WO2000026185A2 (fr) 2000-05-11
AU1907100A (en) 2000-05-22

Similar Documents

Publication Publication Date Title
US4778810A (en) Nasal delivery of caffeine
IS1694B (is) Lyfjablanda til að gefa dýrum um munn sem inniheldur prótonupumpublokkara
IE871981L (en) Programmed release formulation.
GR3029448T3 (en) Compositions for rectal administration containing benzimidazoles and fatty acid salts.
WO2002019999A3 (fr) Compositions et methodes de traitement de dysfonctionnements sexuels
WO2002019969A3 (fr) Acide (5-(2-hydroxy-4-chlorobenzoyl) aminovalerique et ses sels, compositions contenant l'acide et ses sels pour acheminer des agents actifs
WO2000004894A3 (fr) Regime d'administration de phenylacetylglutamine, de phenylacetylisoglutamine et/ou de phenylacetate
WO2001041742A3 (fr) Medication antivirale
NZ514129A (en) Tolperison-containing, pharmaceutical preparation for oral administration
UA66812C2 (uk) Препаративна форма лікарського засобу із регульованим вивільненням активної речовини
WO2000026185A3 (fr) Solution d'omeprazole et methode d'utilisation associee
IE894050L (en) Compound with gastric acid inhibitory effect and process for¹its preparation
NO950134L (no) Formuleringer for oralt administrerte farmasöytiske midler
WO2000048445A3 (fr) Composition pharmaceutique contenant de la desoxypeganine utilisee pour le traitement de la dependance a la nicotine
EP0381181A3 (fr) Système de libération contrôlée de substances actives et son procédé de préparation
WO1991018606A3 (fr) Analgesiques actifs par voie orale ne creant pas d'accoutumance
EP0271151A3 (fr) Formes de dosage de l'azumolène
AU3278800A (en) Pharmaceutical composition containing desoxypeganine for the treatment of drug dependence
ATE212550T1 (de) Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung
AU2907800A (en) Pharmaceutical composition containing desoxypeganine for the treatment of alcoholism
WO2002053097A3 (fr) Compositions pharmaceutiques d'un inhibiteur de la pompe a protons non gastro-resistant avec une combinaison de sel de carbonate et de sel de bicarbonate
WO2002069968A8 (fr) Utilisation nouvelle
AU2001258859A1 (en) Pralmorelin-containing nasal drop preparations
WO2004050019A9 (fr) Compositions et methode de traitement de l'anxiete
WO2001041771A3 (fr) Systeme transdermique contenant de l'acide acetylsalicylique pour le traitement de la migraine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 45, 47 AND 48, DESCRIPTION, REPLACED BY NEW PAGES 45, 47 AND 48; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase